Toripalimab in an advanced non-small cell lung cancer patient with poor general condition after multiline treatment: a case report
Several clinical trials have proven that immunotherapy can improve survival and benefit non-small cell lung cancer (NSCLC) patients.In patients who progress after chemotherapy, immune checkpoint inhibitor ikea university starter pack 2023 (ICI) monotherapy can prolong overall survival compared with patients receiving single-agent chemotherapy.A 61-